Cereblon E3 Ubiquitin Ligase Inhibitor Patent
Summary
The European Patent Office published patent application EP4471033A1 for Gan & Lee Pharmaceuticals' Cereblon E3 ubiquitin ligase inhibitor compounds. The patent covers heterocyclic compositions (C07D derivatives) with applications in cancer treatment. Publication occurred March 25, 2026.
What changed
The EPO published patent EP4471033A1 granting Gan & Lee Pharmaceuticals Co., Ltd. protection for novel Cereblon E3 ubiquitin ligase inhibitor compositions. The compounds fall under multiple IPC classifications including C07D 401/04, 487/04, 491/04, 491/20, 491/107, 498/04, and 498/14, with pharmaceutical applications indicated for A61P 35/00 (antineoplastics) and A61P 35/02 (leukemia). The designated states cover all 35 EPC contracting states including major pharmaceutical markets.
Pharmaceutical companies developing targeted protein degradation therapies or competing E3 ligase inhibitors should review freedom-to-operate implications. Research institutions may consider licensing discussions. The patent does not impose compliance deadlines on generic pharmaceutical manufacturers; IP clearance reviews remain the primary diligence activity for market entrants.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CEREBLON E3 UBIQUITIN LIGASE INHIBITOR
Publication EP4471033A1 Kind: A1 Mar 25, 2026
Applicants
Gan & Lee Pharmaceuticals Co., Ltd.
Inventors
XU, Fuming, CHEN, Wenmin, ZHOU, Guan, YUAN, Hang, LIU, Xiaobing, WANG, Kanghua, LI, Xiaoguang
IPC Classifications
C07D 401/04 20060101AFI20260213BHEP C07D 487/04 20060101ALI20260213BHEP C07D 491/04 20060101ALI20260213BHEP C07D 491/20 20060101ALI20260213BHEP C07D 491/107 20060101ALI20260213BHEP C07D 498/04 20060101ALI20260213BHEP C07D 498/14 20060101ALI20260213BHEP A61P 35/00 20060101ALI20260213BHEP A61K 31/407 20060101ALI20260213BHEP A61K 31/435 20060101ALI20260213BHEP A61K 31/437 20060101ALI20260213BHEP A61K 31/438 20060101ALI20260213BHEP A61P 35/02 20060101ALI20260213BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.